Please check your internet connection and try again.
### Pantoprazole
#### Overview
Pantoprazole is a proton pump inhibitor (PPI) that reduces gastric acid production.
#### Primary Indications
* Gastroesophageal reflux disease (GERD) - symptomatic relief and healing of erosive esophagitis.
* H. pylori eradication (in combination regimens).
* Zollinger-Ellison syndrome and other pathological hypersecretory conditions.
* Prophylaxis of NSAID-induced gastric ulcers in patients at risk.
#### Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily. Some patients may require 40 mg twice daily for healing.
* **H. pylori Eradication:** 40 mg orally twice daily for 7-14 days in combination with antibiotics (e.g., amoxicillin and clarithromycin or clarithromycin and metronidazole).
* **Zollinger-Ellison Syndrome:** Starting dose 40 mg orally or intravenously twice daily. Doses can be titrated up to 240 mg daily.
* **NSAID-Induced Ulcer Prophylaxis:** 20 mg orally once daily.
#### Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1 month to < 5 years:** 20 mg orally once daily.
* **5 years to < 12 years:** 20 mg orally once daily for mild to moderate esophagitis; 40 mg orally once daily for severe esophagitis.
* **12 years and older:** 40 mg orally once daily.
* Intravenous dosing in children is not well established and should be guided by institutional protocols.
#### Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally once daily for severe hepatic impairment. No dose adjustment necessary for mild to moderate impairment.
* **Renal Impairment:** No dose adjustment is typically required.
#### Contraindications
* Hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
#### Adverse Effects
* **Common:** Diarrhea, headache, dizziness, nausea, abdominal pain, flatulence, vomiting, rash.
* **Serious:** _Clostridium difficile_-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia (can be severe, leading to tetany, arrhythmias, seizures), vitamin B12 deficiency, fundic gland polyps.
* **Potential increased risk:** Pneumonia, lupus erythematosus, renal impairment.
#### Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, vitamin B12. Pantoprazole can decrease absorption.
* **CYP2C19 substrates:** Clopidogrel. Pantoprazole may reduce the antiplatelet effect of clopidogrel.
* **Methotrexate:** PPIs may increase methotrexate levels.
* **Voriconazole:** May increase voriconazole levels.
* **CYP3A4 substrates:** Atazanavir, nelfinavir. Pantoprazole can decrease their absorption.
#### Monitoring
* Electrolytes (magnesium, potassium, sodium), especially with prolonged use or concomitant diuretic use.
* Renal function.
* Bone mineral density screening may be considered in patients at risk for osteoporosis with long-term PPI therapy.
* Signs and symptoms of _C. difficile_ infection.
* Vitamin B12 levels with long-term therapy.
#### Clinical Pearls
* Take 30-60 minutes before a meal for optimal efficacy.
* Long-term use of PPIs is associated with increased risks of fractures, _C. difficile_ infection, and hypomagnesemia. Consider the lowest effective dose for the shortest duration necessary.
* Ensure adequate H. pylori testing and eradication regimens are followed.
* Intravenous administration is typically reserved for patients unable to take oral medications.
***
**Disclaimer:** This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete details before making any treatment decisions.
